Oral weight-loss pill The recent 52-week phase 3 trial involved 1,698 adults with type 2 diabetes across six countries
In a statement published alongside the results, Amgen said: Weight loss had not plateaued by 52 weeks, indicating the potential for further weight reduction. It added that improvements were recorded across other cardiometabolic measures, including waist circumference, blood pressure, high-sensitivity C-reactive protein (hs-CRP) and select lipid parameters
This precision approach helps separate marketing narratives from clinically meaningful data and supports informed conversations with qualified providers
Morgan Stanley Research reported that the global GLP-1 market could reach $190 billion by 2035, with China and Brazil in particular seeing possible rapid expansion in uptake
Find your treatment Compounded by state-licensed 503A pharmacies
Nora Al-Amri (verified customer) Rated 5 out of 5 I didnt run into any technical problems while paying for my order